郭宪清, 张丽香, 房立丽. 厄贝沙坦治疗慢性心力衰竭的疗效观察[J]. 心脏杂志, 2009, 21(2): 264-266.
    引用本文: 郭宪清, 张丽香, 房立丽. 厄贝沙坦治疗慢性心力衰竭的疗效观察[J]. 心脏杂志, 2009, 21(2): 264-266.
    shu
    Observations on efficacy of irbesartan in treatment of chronic heart failure[J]. Chinese Heart Journal, 2009, 21(2): 264-266.
    Citation: Observations on efficacy of irbesartan in treatment of chronic heart failure[J]. Chinese Heart Journal, 2009, 21(2): 264-266.
    shu

    厄贝沙坦治疗慢性心力衰竭的疗效观察

    Observations on efficacy of irbesartan in treatment of chronic heart failure

      摘要
    • 摘要: 目的 观察常规治疗的基础上加用厄贝沙坦治疗慢性心力衰竭(CHF)患者的临床疗效。方法 78例CHF患者随机分为两组。对照组给予强心、利尿等治疗，试药组在此基础上加用厄贝沙坦。治疗90 d后观察临床疗效、血压(BP)、心率(HR)、心胸比率变化及超声心动图参数变化。结果 试药组总有效率88%，明显高于对照组(P＜0.05)。试药组心功能的改善明显优于对照组(P＜0.05)，副作用比较轻微。结论 厄贝沙坦治疗CHF安全有效。可作为治疗CHF的一线药物。

       

      Abstract: AIM To observe the clinical efficacy of conventional treatment plus irbesartan in the treatment of patients with chronic heart failure（CHF）. METHODS A total of 78 CHF patients were randomly divided into two groups. The control group was given conventional treatment and the irbesartan group was given conventional treatment plus irbesartan. After 90 days’ treatment, the clinical efficacy, blood pressure (BP), heart rate (HR), cardio-thoracic ratio and echocardiography parameters were observed and compared between the 2 groups. RESULTS The efficiency of the irbesartan group was 88 percent, significantly higher than that of the control group (P<0.05). The heart function of the irbesartan group was significantly better improved than that of the control group(P<0.05) and fewer side effects were found in the irbesartan group. CONCLUSION Irbesartan is safe and effective in the treatment of CHF and can be used as first-line treatment for CHF.

       

      • HTML全文
      • 参考文献(0)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回